Addressing the need for more therapeutic options in neuroendocrine prostate cancer-Reference-Cited by-同舟云学术

Addressing the need for more therapeutic options in neuroendocrine prostate cancer

Published:2023-02-01 Issue:2 Volume:23 Page:177-185
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Kemble Jayson¹,Kwon Eugene D.¹,Karnes R. Jeffrey¹

Affiliation:

1. Department of Urology, Mayo Clinic, Rochester, MN, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2023.2173174

Reference120 articles.

1. American Cancer Society Cancer Facts & Figures [Internet]; 2022[Cited 2022 Aug 15]. Available from https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html

2. National Cancer Institute Cancer Stat Facts:Prostate Cancer [Internet]; 2022 [Cited 2022 Aug 15] Available from: https://seer.cancer.gov/statfacts/html/prost.html

3. Mayo Clinic Gets FDA Approval for New Imaging Agent for Recurrent Prostate Cancer [Internet]. 2012; [Cited 2022 Aug 15] Available from: https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-gets-fda-approval-for-new-imaging-agent-for-recurrent-prostate-cancer/

4. Androgen receptor signaling in prostate cancer development and progression

5. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases;Nuclear Medicine and Biology;2024-02

2. Quadruplet Therapy in De Novo High-Volume Mixed Neuroendocrine Prostate Cancer Using 177Lu-PSMA;Clinical Nuclear Medicine;2024-01-15

3. PSMA PET imaging in the diagnosis and management of prostate cancer;Abdominal Radiology;2023-07-26